Summary
The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK.
The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects, analyses and reports data for use by primary care and specialist services, local and national commissioners to support change and improvement in the quality of services and health outcomes for people with diabetes.
This data release includes the care process and treatment target measurements for 2019-20 (1st January 2019 – 31st March 2020). Data were collected during May and June 2020.
The national report, scheduled for 2021, will contain commentary on the audit findings and recommendations. We will communicate to users when the publication date for this report has been finalised.
GP practice participation in England and Wales has increased from 98.0 per cent in 2018-19 to 99.2 per cent in 2019-20. Diabetes specialist service participation stands at 98 services in 2019-20.
For NDA 2019-20, Diabetes Eye Screening (DES) data has been collected directly from DES providers for the first time. All but one DES provider in England (Liverpool) successfully submitted data, although three providers made partial submissions. For Liverpool, eye examination information secondarily recorded in Primary Care systems has been used, which is likely to be incomplete. The new 'Retinal Screening' care process measure appears in the care process and treatment targets worksheets and also feeds into the new 'All Nine Care Processes' measure, which is reported in addition to the longstanding ‘All Eight Care Processes'.
Please note that there is a potential issue with the SNOMED codes used to identify if a person has had their serum creatinine care process check. Two serum/plasma creatinine codes were removed from the NDA creatinine code set during the universal SNOMED code refresh. This has affected the measurement of creatinine care process completion in a small number of health economies, and thereby has the potential to influence the all eight/nine care process percentages for organisations/areas that still use these codes. To resolve the issue, the NDA business rules are currently being amended to add these codes back into future NDA data extractions.
Last edited: 8 December 2020 10:47 am